Adaptive Biotechnologies (ADPT) vs Beam Therapeutics (BEAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 83.1% versus a loss of 1.4%. Over five years, ADPT leads with a -21.6% price change compared with -73.4% for BEAM. Adaptive Biotechnologies is the larger company by market cap ($4.19 billion vs $2.56 billion), about 1.6 times the size, while Beam Therapeutics is growing revenue faster (+120.0% vs +54.8%).
Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -57.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | BEAM |
|---|---|---|
| Share price | $26.28 | $24.77 |
| Market cap | $4.19B | $2.56B |
| 1-day change | -2.30% | -1.82% |
| YTD return | +61.82% | -10.64% |
| 1-year return | +83.14% | -1.43% |
| 5-year return | -21.55% | -73.41% |
| EPS (TTM) | $-0.41 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $139.74M |
| Revenue growth (YoY) | +54.77% | +120.01% |
| Net income (latest FY) | $-59.50M | $-79.99M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | -274.57% |
| Net margin | -21.48% | -57.24% |
| 52-week high | $30.74 | $38.26 |
| 52-week low | $12.00 | $20.23 |
| Distance from 52-week high | -14.51% | -35.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +7.72% | +110.54% |
| Average volume | 2.39M | 1.91M |
| Shares outstanding | 159.60M | 103.29M |
| Employees | 624 | 540 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed BEAM by 84.6 percentage points over the past year.
- Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -57.2 cents for Beam Therapeutics.
- Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs +54.77%).
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
ADPT vs BEAM FAQ
Which is bigger, Adaptive Biotechnologies or Beam Therapeutics?
Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.19B compared with $2.56B for Beam Therapeutics (BEAM).
Which stock has performed better over the past year, ADPT or BEAM?
ADPT returned +83.14% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Beam Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.